Literature DB >> 23446450

Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity.

Ashlee Van't Veer1, Anita J Bechtholt, Sara Onvani, David Potter, Yujun Wang, Lee-Yuan Liu-Chen, Günther Schütz, Elena H Chartoff, Uwe Rudolph, Bruce M Cohen, William A Carlezon.   

Abstract

Brain kappa-opioid receptors (KORs) are implicated in states of motivation and emotion. Activation of KORs negatively regulates mesolimbic dopamine (DA) neurons, and KOR agonists produce depressive-like behavioral effects. To further evaluate how KOR function affects behavior, we developed mutant mice in which exon 3 of the KOR gene (Oprk1) was flanked with Cre-lox recombination (loxP) sites. By breeding these mice with lines that express Cre-recombinase (Cre) in early embryogenesis (EIIa-Cre) or only in DA neurons (dopamine transporter (DAT)-Cre), we developed constitutive KOR knockouts (KOR(-/-)) and conditional knockouts that lack KORs in DA-containing neurons (DAT-KOR(lox/lox)). Autoradiography demonstrated complete ablation of KOR binding in the KOR(-/-) mutants, and reduced binding in the DAT-KOR(lox/lox) mutants. Quantitative reverse transcription PCR (qPCR) studies confirmed that KOR mRNA is undetectable in the constitutive mutants and reduced in the midbrain DA systems of the conditional mutants. Behavioral characterization demonstrated that these mutant lines do not differ from controls in metrics, including hearing, vision, weight, and locomotor activity. Whereas KOR(-/-) mice appeared normal in the open field and light/dark box tests, DAT-KOR(lox/lox) mice showed reduced anxiety-like behavior, an effect that is broadly consistent with previously reported effects of KOR antagonists. Sensitization to the locomotor-stimulating effects of cocaine appeared normal in KOR(-/-) mutants, but was exaggerated in DAT-KOR(lox/lox) mutants. Increased sensitivity to cocaine in the DAT-KOR(lox/lox) mutants is consistent with a role for KORs in negative regulation of DA function, whereas the lack of differences in the KOR(-/-) mutants suggests compensatory adaptations after constitutive receptor ablation. These mouse lines may be useful in future studies of KOR function.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23446450      PMCID: PMC3682153          DOI: 10.1038/npp.2013.58

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  60 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

2.  Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation.

Authors:  William A Carlezon; Elena H Chartoff
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

Review 3.  Kappa-opioid ligands in the study and treatment of mood disorders.

Authors:  William A Carlezon; Cécile Béguin; Allison T Knoll; Bruce M Cohen
Journal:  Pharmacol Ther       Date:  2009-06-02       Impact factor: 12.310

4.  ΔFosB enhances the rewarding effects of cocaine while reducing the pro-depressive effects of the kappa-opioid receptor agonist U50488.

Authors:  John W Muschamp; Christina L Nemeth; Alfred J Robison; Eric J Nestler; William A Carlezon
Journal:  Biol Psychiatry       Date:  2011-09-29       Impact factor: 13.382

Review 5.  Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence.

Authors:  Brendan M Walker; Glenn R Valdez; Jay P McLaughlin; Georgy Bakalkin
Journal:  Alcohol       Date:  2012-03-27       Impact factor: 2.405

6.  Tropomyosin-related kinase B in the mesolimbic dopamine system: region-specific effects on cocaine reward.

Authors:  Danielle L Graham; Vaishnav Krishnan; Erin B Larson; Ami Graham; Scott Edwards; Ryan K Bachtell; Diana Simmons; Lana M Gent; Olivier Berton; Carlos A Bolanos; Ralph J DiLeone; Luis F Parada; Eric J Nestler; David W Self
Journal:  Biol Psychiatry       Date:  2008-11-06       Impact factor: 13.382

7.  The effects of pentazocine, a kappa agonist, in patients with mania.

Authors:  Bruce M Cohen; Beth Murphy
Journal:  Int J Neuropsychopharmacol       Date:  2007-09-26       Impact factor: 5.176

8.  Inducible Cre mice.

Authors:  Susanne Feil; Nadejda Valtcheva; Robert Feil
Journal:  Methods Mol Biol       Date:  2009

9.  Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens.

Authors:  Jennifer A Dinieri; Christina L Nemeth; Aram Parsegian; Tiffany Carle; Vsevolod V Gurevich; Eugenia Gurevich; Rachael L Neve; Eric J Nestler; William A Carlezon
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

10.  Corticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the κ-opioid receptor antagonist JDTic.

Authors:  Ashlee Van't Veer; Jessica M Yano; F Ivy Carroll; Bruce M Cohen; William A Carlezon
Journal:  Neuropsychopharmacology       Date:  2012-09-05       Impact factor: 7.853

View more
  35 in total

1.  Prefrontal Cortical Kappa Opioid Receptors Attenuate Responses to Amygdala Inputs.

Authors:  Hugo A Tejeda; Ashley N Hanks; Liam Scott; Carlos Mejias-Aponte; Zoë A Hughes; Patricio O'Donnell
Journal:  Neuropsychopharmacology       Date:  2015-05-14       Impact factor: 7.853

2.  Multiple Mild Traumatic Brain Injuries Lead to Visual Dysfunction in a Mouse Model.

Authors:  Abhishek Desai; Huazhen Chen; Hee-Yong Kim
Journal:  J Neurotrauma       Date:  2019-11-08       Impact factor: 5.269

3.  Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias.

Authors:  Kimberly M Lovell; Kevin J Frankowski; Edward L Stahl; Stephen R Slauson; Euna Yoo; Thomas E Prisinzano; Jeffrey Aubé; Laura M Bohn
Journal:  ACS Chem Neurosci       Date:  2015-05-01       Impact factor: 4.418

Review 4.  Opioid modulation of cognitive impairment in depression.

Authors:  Moriah L Jacobson; Hildegard A Wulf; Caroline A Browne; Irwin Lucki
Journal:  Prog Brain Res       Date:  2018-09-18       Impact factor: 2.453

Review 5.  Role of kappa-opioid receptors in stress and anxiety-related behavior.

Authors:  Ashlee Van't Veer; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

Review 6.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

7.  Stress-Induced Reinstatement of Nicotine Preference Requires Dynorphin/Kappa Opioid Activity in the Basolateral Amygdala.

Authors:  Stephanie K Nygard; Nicholas J Hourguettes; Gabe G Sobczak; William A Carlezon; Michael R Bruchas
Journal:  J Neurosci       Date:  2016-09-21       Impact factor: 6.167

8.  Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons.

Authors:  Cullen L Schmid; John M Streicher; Chad E Groer; Thomas A Munro; Lei Zhou; Laura M Bohn
Journal:  J Biol Chem       Date:  2013-06-17       Impact factor: 5.157

Review 9.  Drug withdrawal conceptualized as a stressor.

Authors:  Elena H Chartoff; William A Carlezon
Journal:  Behav Pharmacol       Date:  2014-09       Impact factor: 2.293

Review 10.  Allostatic Mechanisms of Opioid Tolerance Beyond Desensitization and Downregulation.

Authors:  Catherine M Cahill; Wendy Walwyn; Anna M W Taylor; Amynah A A Pradhan; Christopher J Evans
Journal:  Trends Pharmacol Sci       Date:  2016-09-23       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.